Arbutus Biopharma Corporation Common Stock
ABUSStock
$4.74+42.28%52W
Market Cap$923.49M
P/E—
Div yield—
Beta0.59
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-12.43%
Price vs S&P 500 (4W)7.11%
VGM Score67.23
Market Capitalization$923.49M
Earnings Surprise History
Q1 26-0.05est. -0.03
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.22
4.22
4.22
4.22
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ABUSArbutus Biopharma Corporation Common Stock | C | A | C | $4.74 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Arbutus Biopharma is a clinical-stage biopharmaceutical company developing combination therapies for hepatitis B aimed at achieving a functional cure. Key pipeline candidates include imdusiran (AB-729), an RNAi therapeutic, and AB-101, an oral PD-L1 inhibitor. The company leverages proprietary Lipid Nanoparticle (LNP) delivery technology to optimize therapeutic efficacy.